Equities researchers at StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM – Get Rating) in a research report issued on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Trading Up 0.6 %
Shares of Pulmatrix stock opened at $4.68 on Wednesday. The company’s 50-day moving average price is $4.61 and its two-hundred day moving average price is $5.61. Pulmatrix has a 52 week low of $4.03 and a 52 week high of $20.80.
Institutional Trading of Pulmatrix
Several institutional investors and hedge funds have recently bought and sold shares of PULM. Murchinson Ltd. acquired a new stake in Pulmatrix during the 4th quarter worth about $44,000. Parallax Volatility Advisers L.P. acquired a new stake in Pulmatrix during the 4th quarter worth about $43,000. Citadel Advisors LLC acquired a new stake in Pulmatrix during the 2nd quarter worth about $141,000. Finally, Renaissance Technologies LLC raised its holdings in Pulmatrix by 7.3% during the 2nd quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock worth $560,000 after buying an additional 8,300 shares during the period.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
- Get a free copy of the StockNews.com research report on Pulmatrix (PULM)
- If You Hate Speed Cameras, Then You’ll Like Verra Mobility Stock
- Is Sanofi A Buy, Despite Recent Stumbles?
- Institutional Support For TJX Companies May Cap Gains
- Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
- BJ’s Wholesale Club Pops, Will Costco Be Next?
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.